Lactobacillus reuteri strains protect epithelial barrier integrity of IPEC-J2 monolayers from the detrimental effect of enterotoxigenic Escherichia coli
- PMID: 29368445
- PMCID: PMC5789714
- DOI: 10.14814/phy2.13514
Lactobacillus reuteri strains protect epithelial barrier integrity of IPEC-J2 monolayers from the detrimental effect of enterotoxigenic Escherichia coli
Abstract
Lactobacillus reuteri is an inhabitant of the gastrointestinal (GI) tract of mammals and birds and several strains of this species are known to be effective probiotics. The mechanisms by which L. reuteri confers its health-promoting effects are far from being fully understood, but protection of the mucosal barrier is thought to be important. Leaky gut is a state of abnormal intestinal permeability with implications for the pathophysiology of various gastrointestinal disorders. Enterotoxigenic Escherichia coli (ETEC) can invade the intestinal mucosa and induce changes in barrier function by producing enterotoxin or by direct invasion of the intestinal epithelium. Our hypothesis was that L. reuteri can protect the mucosal barrier, and the goal of the study was to challenge this hypothesis by monitoring the protective effect of L. reuteri strains on epithelial dysfunction caused by ETEC. Using an infection model based on the porcine intestinal cell line IPEC-J2, it was demonstrated that pretreatment of the cells with human-derived L. reuteri strains (ATCC PTA 6475, DSM 17938 and 1563F) and a rat strain (R2LC) reduced the detrimental effect of ETEC in a dose-dependent manner, as monitored by permeability of FITC-dextran and transepithelial electrical resistance (TEER). Moreover, the results revealed that ETEC upregulated proinflammatory cytokines IL-6 and TNFα and decreased expression of the shorter isoform of ZO-1 (187 kDa) and E-cadherin. In contrast, pretreatment with L. reuteri DSM 17938 and 1563F downregulated expression of IL-6 and TNFα, and led to an increase in production of the longer isoform of ZO-1 (195 kDa) and maintained E-cadherin expression. Interestingly, expression of ZO-1 (187 kDa) was preserved only when the infected cells were pretreated with strain 1563F. These findings demonstrate that L. reuteri strains exert a protective effect against ETEC-induced mucosal integrity disruption.
Keywords: Lactobacillus reuteri; Enterotoxigenic Escherichia coli (ETEC); IPEC-J2; mucosal integrity.
© 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.
Figures




Similar articles
-
Lactobacillus reuteri 1 Enhances Intestinal Epithelial Barrier Function and Alleviates the Inflammatory Response Induced by Enterotoxigenic Escherichia coli K88 via Suppressing the MLCK Signaling Pathway in IPEC-J2 Cells.Front Immunol. 2022 Jul 14;13:897395. doi: 10.3389/fimmu.2022.897395. eCollection 2022. Front Immunol. 2022. PMID: 35911699 Free PMC article.
-
In Vitro Evaluation of Swine-Derived Lactobacillus reuteri: Probiotic Properties and Effects on Intestinal Porcine Epithelial Cells Challenged with Enterotoxigenic Escherichia coli K88.J Microbiol Biotechnol. 2016 Jun 28;26(6):1018-25. doi: 10.4014/jmb.1510.10089. J Microbiol Biotechnol. 2016. PMID: 26907754
-
Protective effects of Lactobacillus plantarum on epithelial barrier disruption caused by enterotoxigenic Escherichia coli in intestinal porcine epithelial cells.Vet Immunol Immunopathol. 2016 Apr;172:55-63. doi: 10.1016/j.vetimm.2016.03.005. Epub 2016 Mar 5. Vet Immunol Immunopathol. 2016. PMID: 27032504
-
Effect of lactobacilli on paracellular permeability in the gut.Nutrients. 2011 Jan;3(1):104-17. doi: 10.3390/nu3010104. Epub 2011 Jan 12. Nutrients. 2011. PMID: 22254077 Free PMC article. Review.
-
The role of potential probiotic strains Lactobacillus reuteri in various intestinal diseases: New roles for an old player.Front Microbiol. 2023 Feb 2;14:1095555. doi: 10.3389/fmicb.2023.1095555. eCollection 2023. Front Microbiol. 2023. PMID: 36819028 Free PMC article. Review.
Cited by
-
Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms.Front Cell Infect Microbiol. 2023 Aug 18;13:1254198. doi: 10.3389/fcimb.2023.1254198. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37662007 Free PMC article. Review.
-
Targeted Drug Delivery Technologies Potentiate the Overall Therapeutic Efficacy of an Indole Derivative in a Mouse Cystic Fibrosis Setting.Cells. 2021 Jun 25;10(7):1601. doi: 10.3390/cells10071601. Cells. 2021. PMID: 34202407 Free PMC article.
-
Lactobacillus reuteri 1 Enhances Intestinal Epithelial Barrier Function and Alleviates the Inflammatory Response Induced by Enterotoxigenic Escherichia coli K88 via Suppressing the MLCK Signaling Pathway in IPEC-J2 Cells.Front Immunol. 2022 Jul 14;13:897395. doi: 10.3389/fimmu.2022.897395. eCollection 2022. Front Immunol. 2022. PMID: 35911699 Free PMC article.
-
The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.PLoS One. 2024 Nov 1;19(11):e0312464. doi: 10.1371/journal.pone.0312464. eCollection 2024. PLoS One. 2024. PMID: 39485760 Free PMC article. Clinical Trial.
-
Comprehensive mapping of the cell response to E. coli infection in porcine intestinal epithelial cells pretreated with exopolysaccharide derived from Lactobacillus reuteri.Vet Res. 2020 Mar 31;51(1):49. doi: 10.1186/s13567-020-00773-1. Vet Res. 2020. PMID: 32234079 Free PMC article.
References
-
- Ahrné, S. , Molin G., and Axelsson L.. 1992. Transformation of Lactobacillus reuteri with electroporation: studies on the erythromycin resistance plasmid pLUL631. Curr. Microbiol. 24:199–205.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources